Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | PTPRF | P10586 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838054 | 0.98 | CYP11B2 (0.34) | PTPN1PTPRCPTPRFCDC25BCYP11B2 | |
| SCHEMBL25216 | 0.98 | CYP11B2 (0.34) | PTPN1PTPRCPTPRFCDC25BCYP11B2 | |
| SCHEMBL677783 | 0.98 | CYP11B2 (0.34) | PTPN1PTPRCPTPRFCDC25BCYP11B2 | |
| SCHEMBL2911923 | 0.98 | CYP11B2 (0.34) | PTPN1PTPRCPTPRFCDC25BCYP11B2 | |
| SCHEMBL42932 | 0.95 | — | — | |
| SCHEMBL24524 | 0.91 | — | — | |
| SCHEMBL694970 | 0.83 | SLC18A3 (0.44) | SLC18A3 | |
| SCHEMBL17090722 | 0.83 | — | — | |
| SCHEMBL2761445 | 0.83 | — | — | |
| SCHEMBL2814490 | 0.82 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807620-B2 | Quinazolinone compounds and related compounds | Plexium, Inc. (US) | 2023-11-07 | — | — | US | claimed |
| US-11731954-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RES INC (US) | 2023-08-22 | — | — | US | claimed |
| CN-115707712-A | Peptide amide compound, pharmaceutically acceptable salt and stereoisomer thereof, and application thereof | 天地恒一制药股份有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-115466290-A | Narrow-spectrum green phosphorescent platinum complex, preparation method and application thereof, and organic light-emitting diode device | 中国石油化工股份有限公司 | 2022-12-13 | — | — | CN | claimed |
| EP-3897644-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | claimed |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-08-05 | — | — | US | claimed |
| US-11001568-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-05-11 | — | — | US | claimed |
| CN-108276401-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| EP-3383853-B1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR (LXR) BETA AGONISTS FOR TREATING E.G. ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2020-11-04 | — | — | EP | claimed |
| EP-0069385-B1 | USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| CN-86102227-A | The preparation method of 1-alkylamino-2-propyl alcohol that arylolycidyl ethers and 3-replace | — | 1987-02-04 | — | — | CN | claimed |
| EP-0102520-B1 | PROCESS FOR THE INVERSION OF THE CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS, AND OPTICALLY ACTIVE INTERMEDIATES FOR THIS PROCESS | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-10-29 | — | — | EP | claimed |
| EP-0193227-A1 | Process for the preparation of arylglycidyl ethers and 3-substituted 1-alkylamino-2-propanols | GIST-BROCADES N.V. (NL) | 1986-09-03 | — | — | EP | claimed |
| US-4363808-A | N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1982-12-14 | — | — | US | claimed |
| EP-0034116-A2 | N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1981-08-19 | — | — | EP | claimed |
| US-4182911-A | BETA-ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-01-08 | — | — | US | claimed |
| US-3971804-A | ACARICIDES, FUNGICIDES, INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | claimed |
| US-3941829-A | PESTICIDE | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | claimed |
| US-3935250-A | PESTICIDE | CIBA-GEIGY CORPORATION (US) | 1976-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001568-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | PTPN1 654/4885PTPRC 1265/4885PTPRF 1507/4885 |
| US-11731954-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, BMI1 | PTPN1 654/4885PTPRC 1265/4885PTPRF 1507/4885 |
| US-11807620-B2 | Quinazolinone compounds and related compounds | NQO2, COQ8A, PARK7 | PTPN1 2500/4885PTPRC 1365/4885PTPRF 1629/4885 |
| US-20210238161-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, BMI1 | PTPN1 654/4885PTPRC 1265/4885PTPRF 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.